Can You Sell a Patent Pending? What Changes at Grant

Two different questions hide inside "can you sell a patent pending", and the first page of results almost always answers the easy one.

The easy one is whether you can sell your product while the application sits at the patent office. You can. You can market and sell products marked patent pending, the marking is informational rather than a legal weapon, you cannot sue anyone for copying while the application is pending, and the office usually publishes the application eighteen months after filing. That is settled, and it is what most of the ranking pages are about.

The harder question is the one an inventor with a filed application usually means. Can you sell the application itself, as an asset, to somebody else, before it grants? The answer splits in two, and the split is the whole article. Legally, yes, cleanly and without qualification. Commercially, usually not on its own.

Legally, an application is property you can assign

There is a statute for this and it is short. Applications for patent, patents, or any interest therein are assignable in law by an instrument in writing. An application is not a lesser class of property. It can be sold whole, sold in part, mortgaged, or licensed, the same as a granted patent.

That same section carries the trap most first-time sellers walk into. An assignment is void as against a later purchaser for valuable consideration without notice unless it is recorded at the patent office within three months of its date, or before that later purchase happens. Sell the application, forget to record, and a second buyer acting in good faith can end up with better title than the first.

So the paperwork matters more than the price does at this stage. The assignment must convey all right, title, and interest in and to the acquired patents, and recording it at the USPTO is what establishes public notice of who owns the asset now, through the Electronic Patent Assignment System under MPEP 302. Chain of title is the single most common reason a deal goes sideways late: co-inventors who never assigned, an employer agreement nobody read, a defunct company still on the record.

Commercially, a pending application rarely sells alone

This is the part the SERP will not tell you, because most of the pages answering this query are written by people who benefit from you staying optimistic.

From the buy side: buyers are usually not interested in acquiring individual pending applications until the claims are allowed and the patent is subsequently issued, because pending applications are generally too speculative to justify any value, given that the patent or some of the claims may never be approved. It is nearly impossible to sell a portfolio consisting only of pending applications.

Read that twice if you are holding one filed application and nothing else. The market for it is not small. For most assets it is close to empty.

The same buy-side guide gives the exception, and the exception explains the rule. Where an issued US patent is sold together with pending continuation and divisional children, those applications can lift the value of the issued patent by ten to twenty five percent, and buyers are highly reluctant to take a parent without its continuations. Pending applications are worth real money as attachments to something granted. On their own they are an option, and options priced by a cautious counterparty are cheap.

What a buyer is pricing before grant

A buyer looking at a pending application is not valuing an invention. They are valuing three uncertainties, and each one is a discount.

Whether it grants at all

The allowance rate sits around fifty four percent, and at least one rejection in the first office action is close to standard. Roughly a coin toss, before you account for the technology area. A buyer paying full value today for an asset with those odds is making a bet you are getting paid to hand over.

When it grants

Total pendency for allowed patents runs about twenty three to twenty six months, the first office action commonly lands sixteen to twenty months after filing, and a prosecution that needs a request for continued examination stretches total pendency to more than forty four months. Money paid now against a grant three years out is discounted for time as well as for risk.

Which claims survive

This is the one sellers underestimate. Claims narrow during prosecution. That is what prosecution is. The buyer is bidding on a claim set that does not exist yet, drafted by an examiner's objections they cannot read in advance, and they will price the version they fear rather than the version you filed. It is also why the evidence question that decides which route fits what you are holding is harder before grant: you cannot map a product to a claim when the claim is still moving.

The one real right pending status carries

Pending is not entirely toothless. Once the application publishes, the law provides a pre-issuance remedy, and it is worth knowing precisely because so few sellers can describe it.

Under section 154(d), a patent owner can recover a reasonable royalty for use between publication and issue, but only where the infringer had actual notice of the published application, the issued claims are substantially identical to the ones published, and suit is brought no later than six years after the patent issued. The remedy remains underutilised in practice, given how stringent those requirements are.

Three conditions and a deadline, and none of it can be enforced until the patent actually issues. To a buyer that is a contingent claim sitting behind the grant risk above, not a revenue line. It is a reason your asset is not worth zero. It is not a reason it is worth what a granted patent is worth, which is the gap that decides how much a patent actually sells for.

One practical consequence: if publication has already happened and you know of a company practising the published claims, document the notice now. That evidence is worth more at the negotiating table than any argument about the invention's brilliance.

If what you hold is provisional, you hold something narrower

Provisional and pending are not the same asset, and buyers know the difference immediately.

A provisional application has a pendency of twelve months that cannot be extended, provisionals are not examined on their merits, a provisional cannot result in a US patent unless a corresponding nonprovisional is filed within that window, and it becomes abandoned automatically by operation of law when the period expires.

What transfers in a sale, then, is a priority date and an inherited deadline. The buyer is taking on the obligation to file the nonprovisional, at their cost, on your clock, based on a disclosure they did not write. If the provisional is thin, the priority date it supports is thinner than the seller thinks, because you only get priority for what was actually disclosed. Sellers with a provisional and nine months on the clock have the weakest position in this entire market and usually the highest expectations, which is worth knowing before you find out in a negotiation.

Four things to do while it is pending

The SERP hands you a yes and stops. Here is what the yes is actually worth doing.

Build the infringement evidence now. A claim you cannot show being practised by a named company, in volumes worth modelling, is a claim nobody prices. This work does not depend on grant and it is the single highest-return use of the waiting period.

Structure around grant risk instead of arguing about it. An option agreement, staged payments, or an earn-out that triggers on allowance moves the coin toss to where both sides can live with it. A seller demanding a flat price up front is asking the buyer to absorb the risk alone, and the buyer's answer is a lower number or no answer at all.

Consider a licence or a carve-out rather than a whole-asset sale. Rights can be split by industry, territory or field of use, and a carve-out often finds a counterparty where a full assignment stalls, because it lets them pay for only the exposure they need.

Run the arithmetic before spending more. Prosecution costs money and so does everything downstream of it, so weigh what filing actually costs against a realistic view of what a patent is worth to a buyer rather than to a report. If the asset does not survive that comparison, you are at the renew, abandon or monetise decision earlier than you hoped, and reaching it in a month beats reaching it in three years.

How we treat a pending family, including our own

It would be easy for us to tell you pending assets sell well. We hold one, so we will not.

Our first listed family, Edge Assist, is application P00202606645, filed and pending examination, with grant uncertain. Pending application, not granted patent. We say it that way in our own material because the distinction is the substance of this article, and any counterparty who blurs it on their side of a deal is telling you something.

Grant risk is a diligence problem before it is a pricing problem, which is why an asset goes through a validation gate before it reaches a buyer: physics-grade claim reconstruction, detectability analysis and validity probability, benchmarked at 0.76 percent mean absolute percentage error against real-world outcomes. Detectability is the part that maps directly to the evidence problem above. A buyer who can see how infringement would be proven is a buyer who can price a pending claim set instead of discounting it on principle.

On economics, we run brokerage as a process rather than a listing, so the incentive is stated plainly: commission is paid by the seller on completion, with a minimum fee of EUR 5,000 per transaction, and no sale means no fee. Rights can be sold or licensed carved by industry, territory or field of use.

Two limits, in the same breath. EX IX is not a firm of patent attorneys, and a novelty search does not guarantee grant or patentability, so drafting and filing run through an independent licensed attorney of record. And nobody, ourselves included, can promise you a buyer for a pending application. Best efforts is the only honest guarantee in this market, and anyone offering more is selling you the optimism the first page of results already gave you for free.

If your application has not been filed yet, the question changes shape entirely, and that is a different problem: selling an idea that has not been filed at all.

FAQ

Can you sell a provisional patent application? Yes, it is assignable like any other application. What the buyer receives is a priority date and a deadline they inherit: twelve months, not extendable, never examined, and abandoned automatically if no nonprovisional follows. Price accordingly, and expect the buyer to read the disclosure closely, since priority only covers what was actually described.

Do you have to tell the patent office you sold your application? Recording is not what makes the transfer valid between you and the buyer, but skipping it is dangerous. An unrecorded assignment is void against a later good-faith purchaser unless recorded within three months of its date or before that purchase, so record it through the Electronic Patent Assignment System as part of closing, not afterwards.

Do you stay the inventor after selling a pending application? Yes. Inventorship and ownership are separate. An assignment moves all right, title and interest to the buyer, and the named inventors on the application do not change because the asset changed hands. Inventorship is a factual question about who conceived the invention, not a tradeable interest.

What happens to the price if the application is rejected? That depends entirely on the structure you agreed. It is exactly why buyers prefer options, staged payments and earn-outs that pay on allowance rather than on signature. A flat price paid up front means the buyer already discounted the roughly even chance of grant into the number you accepted.